Oxford BioMedica logo

OXB - Oxford BioMedica Share Price

1024p -18.0  -1.7%

Last Trade - 07/05/21

Mid Cap
Market Cap £844.0m
Enterprise Value £811.1m
Revenue £87.7m
Position in Universe 475th / 1821
Unlock OXB Revenue
Relative Strength (%)
1m +1.82%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -9.10%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
15.9 27.8 37.6 66.8 64.1 87.7 120.5 125.6 +40.7%
Balance Sheet
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020, OxfordBioMedica plc revenues increased 37% to £87.7M. Net lossdecreased 61% to £6.2M. Revenues reflect Platform segmentincrease of 71% to £87.1M, Rest of world segment increaseof 100% to £34.9M, Europe segment increase of 13% to£52.8M. Lower net loss reflects Platform segment incometotaling £2M vs. loss of £20.2M.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for OXB
Graphical History


OXB Revenue Unlock OXB Revenue

Net Income

OXB Net Income Unlock OXB Revenue

Normalised EPS

OXB Normalised EPS Unlock OXB Revenue

PE Ratio Range

OXB PE Ratio Range Unlock OXB Revenue

Dividend Yield Range

OXB Dividend Yield Range Unlock OXB Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
OXB EPS Forecasts Unlock OXB Revenue
Profile Summary

Oxford BioMedica Plc is a gene and cell therapy company. The Company and its subsidiaries has developed lentiviral vector delivery platform (LentiVector), which the Company leverages to develop in vivo and ex vivo products both in-house and with partners. Its LentiVector delivery platform has created a portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, liver and central nervous system (CNS) disorders. The Company's product pipeline includes OXB-302, OXB-203, OXB-204 and OXB-103 and OXB-401 and addresses neurodegenerative and a range of cancers. The Company has also developed partnership with various pharmaceutical companies to develop potential gene and cell therapy products. Its partnered products include AXO-LENTI-PD, SAR 422459 and SAR421869.

Last Annual December 31st, 2020
Last Interim December 31st, 2020
Incorporated September 20, 1996
Public Since November 15, 1996
No. of Shareholders: n/a
No. of Employees: 673
OXB Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for OXB
Upcoming Events for OXB
Thursday 27th May, 2021
Oxford BioMedica PLC Annual Shareholders Meeting
Wednesday 23rd June, 2021 Estimate
Oxford BioMedica PLC Annual Shareholders Meeting
Wednesday 15th September, 2021 Estimate
Half Year 2021 Oxford BioMedica PLC Earnings Release
Frequently Asked Questions for Oxford BioMedica
What is the Oxford BioMedica share price?

As of 07/05/21, shares in Oxford BioMedica are trading at 1024p, giving the company a market capitalisation of £844.0m. This share price information is delayed by 15 minutes.

How has the Oxford BioMedica share price performed this year?

Shares in Oxford BioMedica are currently trading at 1024p and the price has moved by 41.24% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Oxford BioMedica price has moved by 14.66% over the past year.

What are the analyst and broker recommendations for Oxford BioMedica?

Of the analysts with advisory recommendations for Oxford BioMedica, there are there are currently 3 "buy" , 2 "hold" and 1 "sell" recommendations. The overall consensus recommendation for Oxford BioMedica is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Oxford BioMedica next release its financial results?

Oxford BioMedica is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Oxford BioMedica dividend yield?

Oxford BioMedica does not currently pay a dividend.

Does Oxford BioMedica pay a dividend?

Oxford BioMedica does not currently pay a dividend.

When does Oxford BioMedica next pay dividends?

Oxford BioMedica does not currently pay a dividend.

How do I buy Oxford BioMedica shares?

To buy shares in Oxford BioMedica you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Oxford BioMedica?

Shares in Oxford BioMedica are currently trading at 1024p, giving the company a market capitalisation of £844.0m.

Where are Oxford BioMedica shares listed? Where are Oxford BioMedica shares listed?

Here are the trading details for Oxford BioMedica:

Country of listing: United Kingdom
Exchange: LSE
Ticker Symbol: OXB
What kind of share is Oxford BioMedica?

Based on an overall assessment of its quality, value and momentum, Oxford BioMedica is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Oxford BioMedica share price forecast 2021?

Shares in Oxford BioMedica are currently priced at 1024p. At that level they are trading at 6.36% discount to the analyst consensus target price of 1,093.55.

Analysts covering Oxford BioMedica currently have a consensus Earnings Per Share (EPS) forecast of 0.04071 for the next financial year.

How can I tell whether the Oxford BioMedica share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Oxford BioMedica. Over the past six months, the relative strength of its shares against the market has been 8.87%. At the current price of 1024p, shares in Oxford BioMedica are trading at 11.86% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Oxford BioMedica PE Ratio?

We were not able to find PE ratio data for Oxford BioMedica.

Who are the key directors of Oxford BioMedica?

Oxford BioMedica's management team is headed by:

John Dawson - CEO
Andrew Heath - NVC
Stuart Paynter - CFO
Robert Ghenchev - NED
Jason Slingsby - OTH
James Miskin - CTO
Kyriacos Mitrophanous - CSO
Nick Page - COO
Dmitry Zamoryakhin - OTH
Helen Stephenson-Ellis - CHO
Natalie Walter - GCN
Roch Doliveux - NEC
Siyamak Rasty - NED
Dame Kay Davies - NED
Who are the major shareholders of Oxford BioMedica?

Here are the top five shareholders of Oxford BioMedica based on the size of their shareholding:

M & G Investment Management Ltd. Investment Advisor
Percentage owned: 12.11% (9.98m shares)
Vulpes Investment Management Private Limited Hedge Fund
Percentage owned: 12.01% (9.90m shares)
Novo Holdings A/S Venture Capital
Percentage owned: 9.4% (7.75m shares)
M&G Recovery Fund Mutual Fund
Percentage owned: 9.16% (7.55m shares)
Liontrust Investment Partners LLP Investment Advisor
Percentage owned: 4.47% (3.68m shares)
Similar to OXB
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.